Spun out of George Church's lab, this biotech upstart is mapping the AAV universe for Novartis, Sarepta to gaze

Press
May 11, 2020
Endpoints News
TOC LINK
TOC LINK
Press
Published 
May 11, 2020

More like this

Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements
Dyno Therapeutics
April 27, 2026

Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements
Dyno Therapeutics
April 27, 2026

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements
Dyno Therapeutics
May 13, 2026

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements
Dyno Therapeutics
May 13, 2026

Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)

Announcements
Dyno Therapeutics
May 13, 2026

Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)

Announcements
Dyno Therapeutics
May 13, 2026

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Announcements
Dyno Therapeutics
April 8, 2026

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Announcements
Dyno Therapeutics
April 8, 2026
™ 
343 Arsenal St
Watertown, MA 02472
© Dyno 2025
Privacy PolicyTerms + Conditions